Anticancer Agents  Design, Synthesis and Evaluation 

<br/><br/><br/>English[eng] 
<br/><br/><label>Subjects--Topical Terms: </label><br/>benzofurans||chemical synthesis||cytotoxic properties||HeLa||MOLT-4||K562||anticancer||anti-neuroinflammation||coumarin||dihydroartemisinin||flavonoids||allene||E-stereoselective||regioselective||anti-cancer activity||cyanopyridone||substituted pyridine||pyridotriazine||pyrazolopyridine||thioxotriazopyridine||anticancer activity||HepG2||antitumor activity||computational docking||MDM2-p53 interaction||xanthones||yeast-based assays||estrone derivatives||hydrazine||N-substituted pyrazoline||anti-ovarian cancer||topoisomerase II inhibitor||kinase inhibitor||antiproliferative agent||urea||synthesis||antiproliferative activity||apoptosis||indoleamine 2,3-dioxygenase||inhibitor||anti-tumor||immune modulation||tryptophan metabolism||taxoids||βIII-tubulin||P-glycoprotein||drug resistance||thiopene||thienopyrimidinone||thiazolidinone||breast cancer||benzofuran–pyrazole||nanoparticles||cytotoxic activity||PARP-1 inhibition||3,6-dibromocarbazole||5-bromoindole||carbazole||actin||migration||Thienopyrimidine||Pyrazole||PI3Kα inhibitor||quinazolin-4(3H)-one||quinazolin-4(3H)-thione||Schiff base||antioxidant activity||DFT study||ortho-quinones||beta-lapachone||tanshione IIA||PI3Ks||PI3Kδ inhibitors||2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide||anticancer agents||protein–protein interactions||virtual screening||mimetics||drug discovery||bivalency||polyvalency||antitumor||cell cycle||ovarian cancer||P-MAPA||IL-12||TLR signaling||inflammation||chemoresistance||4-(pyridin-4-yloxy)benzamide||1,2,3-triazole||c-Met||natural product||anticancer agent||zampanolide||Talazoparib||PARP inhibitor||prodrug||o-nitro-benzyl||photoactivatable protecting groups||salinomycin||overcoming drug resistance||tumor specificity||synergy||5-fluorouracil||gemcitabine||amides/esters||colchicine analogs||thiocolchicine||colchiceine||antimitotic agents||hydrates||dihydropyranoindole||HDAC inhibitors||neuroblastoma||aromatase||MCF-7||NIH3T3||benzimidazole||triazolothiadiazine||docking||ADME||organosilicon compounds||SILA-409 (Alis-409)||SILA-421 (Alis-421)||multidrug resistance (MDR) reversal||ABCB1 (P-glycoprotein)||colon cancer||colchicine amide||colchicine sulfonamide||tubulin inhibitors||docking studies||crystal structure||PROTACs||protein degradation||IGF-1R||Src||protein kinase||phenylpyrazolopyrimidine||enzyme inhibition||molecular simulation||androgen receptor||prostate cancer||enzalutamide||apalutamide||darolutamide||triple-negative breast cancer||cytotoxicity||chrysin analogues||flavonoid||anticancer compounds